CEACAM5 and metastatic colorectal cancer: Su et al. developed a novel prognostic index by multiplying carcinoembryonic antigen values and NLR values and determined that the derived index had a significant association with OS in patients undergoing regorafenib treatment for metastatic colorectal cancer [25].